Published in
American Society for Clinical Investigation, Journal of Clinical Investigation, 11(130), p. 5875-5892, 2020
DOI: 10.1172/jci134132
Links
Tools
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
Journal article published in 2020 by
Evon Poon 
,
Tong Liang,
Yann Jamin ,
Susanne Walz,
Colin Kwok ,
Anne Hakkert,
Karen Barker,
Zuzanna Urban ,
Khin Thway,
Rhamy Zeid,
Albert Hallsworth,
Gary Box,
Marli E. Ebus,
Marco P. Licciardello ,
Yordan Sbirkov
and other authors.
,
Tong Liang,
Yann Jamin ,
Susanne Walz,
Colin Kwok ,
Anne Hakkert,
Karen Barker,
Zuzanna Urban ,
Khin Thway,
Rhamy Zeid,
Albert Hallsworth,
Gary Box,
Marli E. Ebus,
Marco P. Licciardello ,
Yordan Sbirkov
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 